Cargando…
Clinical stage molecule PT150 is a modulator of glucocorticoid and androgen receptors with antiviral activity against SARS-CoV-2.
PT150 is a clinical-stage molecule, taken orally, with a strong safety profile having completed Phase 1 and Phase 2 clinical trials for its original use as an antidepressant. It has an active IND for COVID-19. Antiviral activities have been found for PT150 and other members of its class in a variety...
Autores principales: | Theise, Neil D., Arment, Anthony R., Chakravarty, Dimple, Gregg, John M. H., Jacobson, Ira M., Jung, Kie Hoon, Nair, Sujit S., Tewari, Ashutosh K., Thurston, Archie W., Van Drie, John, Westover, Jonna B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7738205/ https://www.ncbi.nlm.nih.gov/pubmed/33305659 http://dx.doi.org/10.1080/15384101.2020.1859752 |
Ejemplares similares
-
Racial disparity in prostate cancer in the African American population with actionable ideas and novel immunotherapies
por: Dovey, Zachary S., et al.
Publicado: (2021) -
Why do African–American men face higher risks for lethal prostate cancer?
por: Nair, Sujit S., et al.
Publicado: (2022) -
Increased Hospitalization and Mortality from COVID-19 in Prostate Cancer Patients
por: Chakravarty, Dimple, et al.
Publicado: (2021) -
A randomized trial of safety and pharmacodynamic interactions between a selective glucocorticoid receptor antagonist, PT150, and ethanol in healthy volunteers
por: Morice, Claire, et al.
Publicado: (2021) -
Sex differences in SARS-CoV-2 infection rates and the potential link to prostate cancer
por: Chakravarty, Dimple, et al.
Publicado: (2020)